Articles related to CARDIORENAL OUTCOMES

Intensive blood-pressure lowering reduced major cardiovascular events similarly in adults with and without chronic kidney disease, without increasing kidney failure risk, although sustained declines in estimated glomerular filtration rate occurred more frequently.

The 2026 ESC heart failure guidelines redefine ejection-fraction phenotypes, formalize stages A through D, and broaden foundational therapy recommendations, including SGLT2 inhibitors and mineralocorticoid receptor antagonists across defined clinical settings.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

A 31,000-patient observational study found that dihydropyridine calcium-channel blockers were associated with a 33% higher risk of major adverse kidney events in type 2 diabetes patients already on RASi and SGLT2i therapy.

A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.